The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The target reach is of more than 30 million young people and caregivers across 21 countries
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Global specialty pipeline accelerates growth
Highlighting KEYTRUDA & expanding cancer pipeline
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Nearly one in five women worldwide are now living with obesity
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
Subscribe To Our Newsletter & Stay Updated
